SND-586

SND-586 is a preclinical-stage small molecule drug candidate being developed by Pelago Bioscience AB. The compound is positioned for potential therapeutic applications across several broad disease areas, including neoplasms (cancer), metabolic diseases, endocrine system disorders, immune system diseases, and hemic and lymphatic diseases. While specific details regarding its biological target and mechanism of action have not been publicly disclosed, the development of SND-586 is closely linked to Pelago's proprietary Cellular Thermal Shift Assay (CETSA) technology. This platform is used to assess and validate drug-target engagement in a physiological environment, suggesting that SND-586 was identified or optimized using this methodology. As of current reporting, the asset remains in early-stage development with no clinical trial data available.